Teva Pharmaceutical Industries Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 2/6
Teva Pharmaceutical Industries şirketinin toplam hissedar öz sermayesi $6.4B ve toplam borcu $19.0B olup, bu da borç-öz sermaye oranını 297.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $41.8B ve $35.4B dir. Teva Pharmaceutical Industries 'in FAVÖK'ü $3.7B faiz karşılama oranı 4 dur. Şirketin $3.3B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.
Anahtar bilgiler
297.3%
Borç/özkaynak oranı
US$18.98b
Borç
| Faiz karşılama oranı | 4x |
| Nakit | US$3.32b |
| Eşitlik | US$6.38b |
| Toplam yükümlülükler | US$35.37b |
| Toplam varlıklar | US$41.76b |
Son finansal sağlık güncellemeleri
Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?
Oct 21
Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Jul 12Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Recent updates
Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt
Oct 23Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?
Oct 21Cheap Teva Stock Should Reward Patient Investors
Sep 09Teva's Transformation: From Generics Leader To Branded Drug Innovator
Aug 14Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 02Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs
Jul 26Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Jul 12Teva Pharmaceutical: Buy This Bargain Before It's Gone
Jun 07Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
May 14Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)
May 09Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26Teva Pharmaceutical Industries: Potential Outweighs Concerns
Mar 25Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26A Review Of Teva's Prospects
Feb 15Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry
Jan 07These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
Dec 08Teva: Deeply Undervalued FCF Machine
Nov 20Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Feb 20What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
Dec 28Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex
Dec 16Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit
Nov 10Teva Pharmaceutical to pay New York $523M as part of opioid settlement
Nov 03Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: TEVA 'nin kısa vadeli varlıkları ( $12.3B ) kısa vadeli yükümlülüklerini ( $13.8B ) kapsamıyor.
Uzun Vadeli Yükümlülükler: TEVA 'un kısa vadeli varlıkları ( $12.3B ) uzun vadeli yükümlülüklerini ( $21.6B ) karşılamamaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: TEVA 'nin net borç/öz sermaye oranı ( 245.3% ) yüksek olarak değerlendiriliyor.
Borcun Azaltılması: TEVA şirketinin borç/öz sermaye oranı son 5 yılda 180.5% seviyesinden 297.3% seviyesine yükseldi.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: Kârsız olan TEVA mevcut pozitif serbest nakit akışı seviyesini koruduğu takdirde 3 yıldan fazla yetecek nakit pistine sahip olacaktır.
Tahmini Nakit Akışı: TEVA kârlı değildir ancak serbest nakit akışının pozitif olması ve yılda % 1.8 oranında büyümesi nedeniyle 3 yıldan fazla bir süre yetecek nakit akışına sahiptir.